Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Participants will be randomized in a 1:1 ratio to receive either SHR‐1316 + carboplatin + etoposide or placebo + carboplatin + etoposide for 4‐6 cycles in the induction phase followed by maintenance with SHR‐1316 or placebo until progressive disease (PD) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Treatment can be continued until persistent radiographic PD or or unacceptable toxicity.
Epistemonikos ID: a0586c80db5101b41e68362f8d16f1fb07ebe99c
First added on: Jan 05, 2024